Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Kanada - Inggris - Health Canada

jamp pharma corporation - tranexamic acid - tablet - 500mg - tranexamic acid 500mg - hemostatics

Kanada - Inggris - Health Canada

eugia pharma inc. - tranexamic acid - solution - 100mg - tranexamic acid 100mg

Kanada - Inggris - Health Canada

eugia pharma inc. - tranexamic acid - solution - 100mg - tranexamic acid 100mg

Kanada - Inggris - Health Canada

eugia pharma inc. - tranexamic acid - solution - 100mg - tranexamic acid 100mg

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - tranexamic acid 100 mg/ml;   - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: - prostatectomy and bladder surgery - epistaxis - management of dental extraction in patients with coagulopathies - ulcerative colitis - gastrointestinal haemorrhage. general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: - in obstetrical complications such as abruption placentae and post-partum haemorrhage - in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase. for the reduction of peri- and post-operative blood loss and the need for blood transfusion in adult patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. for the reduction of peri- and post-operative blood loss and the need for blood transfusion in paediatric patients undergoing cardiac surgery.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - lysteda® (tranexamic acid, usp) tablets is indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies (14) ]. prior to prescribing lysteda, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe lysteda to women who are - using combination hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic val

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - tranexamic acid - oral tablet - 500mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - tranexamic acid - oral tablet - 500mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - tranexamic acid - oral tablet - 500mg